CEO exercised or converted 4,991 RMD derivative securities | OQRO
Why it stands out Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
Transaction date Jul 7, 2026
Reporting period Not applicable
Filed with the SEC Jul 9, 2026 CEO Option exercise
Context Classification option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0000943819-26-000038
Filed / recorded
Jul 9, 2026, 3:40 PM UTC
Added to OQRO Oct 2, 2026, 12:28 PM UTC
Data quality Verified: identifiers matched exactly
Reporting person Michael J. Farrell
Relationship Director, Officer
Officer title Chairman and CEO
Security ResMed Common Stock Options
Table Derivative (Table II)
Transaction date Jul 7, 2026
Acquired / disposed Disposed (D)
Footnotes from the filing The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Represents date options first become exercisable. Options vest 1/3 per year.
Around the same time 2mo ago
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Director sold ~$1.8M of ResMed|
2mo ago 2mo ago
Held by the filer's joint per the disclosure. Disclosed 824 days after the transaction; reported as an official range, not an exact amount.
Congress trade